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Abstract
Background: Age is one of the most important risk factors for developing breast cancer. However, age-related
changes in normal breast tissue that potentially lead to breast cancer are incompletely understood. Quantifying
tissue-level DNA methylation can contribute to understanding these processes. We hypothesized that occurrence
of breast cancer should be associated with an acceleration of epigenetic aging in normal breast tissue.
Results: Ninety-six normal breast tissue samples were obtained from 88 subjects (breast cancer = 35 subjects/40
samples, unaffected = 53 subjects/53 samples). Normal tissue samples from breast cancer patients were obtained
from distant non-tumor sites of primary mastectomy specimens, while samples from unaffected women were
obtained from the Komen Tissue Bank (n = 25) and from non-cancer-related breast surgery specimens (n = 28).
Patients were further stratified into four cohorts: age < 50 years with and without breast cancer and age ≥ 50 with
and without breast cancer. The Illumina HumanMethylation450k BeadChip microarray was used to generate
methylation profiles from extracted DNA samples. Data was analyzed using the “Epigenetic Clock,” a published
biomarker of aging based on a defined set of 353 CpGs in the human genome. The resulting age estimate, DNA
methylation age, was related to chronological age and to breast cancer status.
The DNAmAge of normal breast tissue was strongly correlated with chronological age (r = 0.712, p < 0.001). Compared to
unaffected peers, breast cancer patients exhibited significant age acceleration in their normal breast tissue (p = 0.002).
Multivariate analysis revealed that epigenetic age acceleration in the normal breast tissue of subjects with cancer
remained significant after adjusting for clinical and demographic variables. Additionally, smoking was found to be
positively correlated with epigenetic aging in normal breast tissue (p = 0.012).
Conclusions: Women with luminal breast cancer exhibit significant epigenetic age acceleration in normal adjacent
breast tissue, which is consistent with an analogous finding in malignant breast tissue. Smoking is also associated with
epigenetic age acceleration in normal breast tissue. Further studies are needed to determine whether epigenetic age
acceleration in normal breast tissue is predictive of incident breast cancer and whether this mediates the risk of
chronological age on breast cancer risk.
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Background
Breast cancer represents 15% of all new cancer cases in the
US, and with 252,710 estimated new cases in 2017, it has
the highest cancer-related incidence in women in the coun-
try [1]. Age is one of the strongest risk factors for develop-
ing breast cancer and is most frequently diagnosed among
women aged 55 to 64. However, the factors that mediate
the effect of chronological age on breast cancer are not
fully known. Since epigenetic changes are one of the hall-
marks of aging, it is plausible that age-related epigenetic
changes may play a role in conferring breast cancer risk.
Historically, studies of the effect of age on breast cancer
have been limited by the lack of suitable molecular bio-
markers of tissue age. Several studies have explored
whether telomere shortening is associated with increased
risk and earlier occurrence of familial breast cancer, but
the reported effect sizes are relatively weak and require
additional validation [2, 3].
It has recently been recognized that DNA methylation
levels lend themselves for defining a highly accurate bio-
marker of tissue age (“epigenetic clock”) that applies to all
human tissues and cell types [4]. This epigenetic biomarker
is based on the weighted average DNA methylation level of
353 cytosine-phosphate-guanines (CpGs). The age estimate
(in unit of years) is referred to as “DNA methylation age”
(DNAmAge) or “epigenetic age.” By contrasting DNAmAge
with an individual’s chronological age, one can define a
measure of epigenetic age acceleration. For instance, a
woman whose blood tissue has a higher DNAmAge than
expected based upon her chronological age is said to
exhibit positive age acceleration in blood. Recent studies
support the idea that these measures are at least passive
biomarkers of biological age. To elaborate, the epigenetic
age of blood has been found to be predictive of all-cause
mortality [2, 3], lung cancer [5], frailty [6], and cognitive
and physical functioning [7]. Further, the utility of the
epigenetic clock method using various tissues and organs
has been demonstrated in several applications including
Alzheimer’s disease [8], centenarian status [8, 9], obesity
[10], menopause [11], and osteoarthritis [12].
An increasing body of literature suggests that epi-
genetic age acceleration in blood is predictive of vari-
ous cancers [5, 13] including breast cancer [14].
Cancer greatly disrupts the epigenetic age of the af-
fected (malignant) tissue [4, 15]. While some cancer
types are associated with positive age acceleration,
others are associated with negative age acceleration
[4, 15]. We have recently shown that malignant
breast cancer samples from luminal breast cancer ex-
hibit strong positive age acceleration, which contrasts
sharply with the negative age acceleration in basal
breast cancers [4, 15]. However, it is unknown
whether these age acceleration effects can also be ob-
served in a normal adjacent tissue. Here, we address
this question by correlating epigenetic age acceler-
ation in normal breast tissue samples with breast can-
cer disease status. We find that normal breast tissue
samples from breast cancer cases exhibit positive age
acceleration compared to normal breast tissue sam-
ples from controls. These age acceleration effects are
independent of various confounders such as chrono-
logical age, ethnicity, age at menarche, number of live
births, and menstrual status. In a secondary analysis,
we found that smoking is associated with positive epi-
genetic age acceleration in normal breast tissue.
Methods
Study specimens
This was a multicenter cross-sectional study performed
on fresh frozen samples of normal breast tissue that were
collected from four cohorts of women, namely age
< 50 years with and without breast cancer and age ≥ 50
with and without breast cancer. Normal breast tissue in
patients with breast cancer was defined as histologically
benign tissue at least 3 cm away from the primary tumor
margin. These samples were obtained prospectively from
patients undergoing primary total mastectomy for stage
0–III breast cancer at the Yale Breast Center. Eligible pa-
tients were those who had not received chemotherapy, ra-
diation, or endocrine therapy prior to surgery. Normal
breast tissue from non-cancer patients was obtained from
the Susan G. Komen Tissue Bank at IU Simon Cancer
Center and prospectively from women presenting for re-
duction mammoplasty at Yale New Haven Hospital.
Clinical data collected for each subject included age,
height, weight, ethnicity, medical history, reproductive
history, tobacco and alcohol use, family history of
breast cancer, and tumor characteristics. The study
was approved by the institutional review board, and
written informed consent was obtained from all pa-
tients in compliance with the protocol.
The Susan G. Komen Tissue Bank (KTB) is a
unique resource that has helped in the understanding
of normal breast biology. All participant samples from
the KTB group are unaffected tissue donors without a
cancer history, and study samples were anonymized
in accordance to the protocol. The study population
from the hospital prospective cohort included women
from all age groups that consented for the study, and
patients that had received neoadjuvant treatment were
excluded. The tissue samples were further categorized
based on tumor molecular subtypes.
Tissue processing
The breast tissue was sampled as six individual core
pieces that were histologically benign, and within 5 min
of procurement, each piece was embedded in a cassette
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that was subsequently placed in a 10% buffered formalin
solution and stored at room temperature. The cores
were then flash frozen with liquid nitrogen at − 166.2 °C.
The cryo-vials with at least 50 mg of breast tissue per
sample were shipped to the lab where the DNA was ex-
tracted using the Qiagen All Prep Universal kit. Samples
were processed as whole tissue, and DNA was
re-extracted from samples that had low DNA yield be-
cause of increased fatty tissue. The extracted DNA was
then used for bisulfite sequencing experiments.
DNA extraction and methylation studies
Zymo EZ DNA methylation KIT (Zymo Research,
Orange, CA, USA) was used to obtain bisulfite conver-
sion and subsequent hybridization, and scanning was
performed with the HumanMethylation450k BeadChip
(Illumina, San Diego, CA) and iScan (Illumina) accord-
ing to the manufacturers’ protocol with standard
settings. DNA methylation levels (β) were quantified
using the “noob” normalization method [16]. Specifically,
the β value was calculated as a ratio of the intensity of
fluorescent signals from the methylated and the
unmethylated sites:
β =max (M,0)/[max (M,0) + max (U,0) + 100].
M =methylated signals.
U = unmethylated signal.
Thus, β values ranged from 0 to 1 (completely
unmethylated to completely methylated).
DNAmAge was then calculated, which has been
described in detail elsewhere [4]. Briefly, the epigenetic
clock is defined as a prediction method of age based on the
DNA methylation levels of 353 CpGs. Predicted age,
referred to as DNAmAge, correlates with chronological age
in multiple different cell types (CD4+ T cells, monocytes, B
cells, neurons), tissues, and organs, including whole blood,
brain, breast, kidney, liver, and lung [4].
Internal validation cohort
Five sets of duplicate samples were analyzed from the
cancer cohort in order to examine for concordance.
Statistical methods
Patient variables
Baseline patient characteristics were compared in the
cancer and control arm to identify any differences in the
study cohort. The continuous variables were analyzed
using the unpaired student t test and presented as mean
values with 95% confidence intervals. The categorical
variables were analyzed using the chi-square test and
presented as frequency percentages. A multivariate logistic
regression analysis was then performed to identify signifi-
cant co-variates for the breast cancer status.
Epigenetic variables
Despite high correlations, DNAmAge estimates can de-
viate substantially from chronological age at the individ-
ual level; by adjusting for chronological age, we can
arrive at a measure of epigenetic age acceleration. DNA
methylation age was regressed on chronological age (at
the time of breast sample collection) using linear
regression. Age acceleration was then defined as raw
residuals resulting from the model. Thus, a positive
or negative value indicates that a given breast sample
is older or younger than expected based on
chronological age, respectively. This measure of age
acceleration is not correlated with chronological age
(r = 0) and has a mean value of zero. All measures
were calculated using a previously published online
version of the DNAmAge calculator. We further cal-
culated the mean methylation levels in the two
groups. Pearson correlation statistic of methylation
levels against age was calculated for cancer and con-
trol groups. Non-parametric tests were performed to
test for mean differences in all the epigenetic vari-
ables within the two cohorts.
Regression models (univariate, multivariate, and IPWRA)
A linear regression model was plotted to define the
collinearity of the DNAmAge with the age variable. The
residuals from the plot were utilized to define the age
acceleration residuals as mentioned before. A univariate
and multivariate linear regression analysis was then
performed to identify predictors of DNAmAge and age
acceleration residuals. The p value < 0.05 was consid-
ered statistically significant. A regression adjustment
model with inverse probability weighting (IPWRA) was
created to address for the potential confounding vari-
ables. This treatment effects model was further boot-
strapped for 500 repetitions to identify the 95%
confidence intervals of the average treatment effect in
population and the potential-outcome means. Average
treatment effect in this model can be defined as the
additional DNAmAge years of the tissue sample in
breast cancer patients compared to controls in a
matched population.
Predictive function of epigenetic variables—ROC curves
Receiver operating characteristic (ROC) were plotted
for breast cancer status as the reference variable and
age, DNAmAge, mean methylation by sample, age ac-
celeration difference, and age acceleration residuals as
classification variables. DeLong method was used to
calculate the standard errors, and binomial confidence
intervals were calculated. The ROC curves were plot-
ted based on the binomial fit models, and the AUC
was calculated. The sensitivity and specificity of the
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most predictive epigenetic variable was then calculated
based on the ROC curve.
All the tables, graphs and statistical analysis was per-
formed using STATA version 15.1 (StataCorp LLC, TX,
USA). Original datasets used for statistical analysis are
included as Additional files 1 and 2.
Results
Sample characteristics
Ninety-six normal breast tissue samples were obtained
from 88 subjects (breast cancer = 35 subjects/40
samples, unaffected = 53 subjects/53 samples). Normal
tissue samples from breast cancer patients were
obtained from distant non-tumor sites of primary
mastectomy specimens, while samples from unaffected
women were obtained from the Komen Tissue Bank
(n = 25) and from non-cancer related breast surgery
specimens (n = 28). Three patients that received
neoadjuvant chemotherapy in the cancer arm were
excluded from analysis. Five additional samples were
taken from specimens with breast cancer to serve as
internal controls for studying any variations within
the breast tissue. Samples from the breast cancer
patients were classified as the “cancer arm,” and those
from unaffected patients were classified as the
“control arm.”
Patient demographics
The baseline characteristics for the cancer arm and
control arm have been summarized in Table 1. The
mean age of patients was 49.7 years versus 45.9 years
in the cancer arm and the control arm, respectively
(p = 0.126). Most of the patients in our study cohort
were Caucasian (86%) and non-Hispanic (91.4%). The
average body mass index of the cancer group was
27 kg/m2. Forty percent of patients were
ever-smokers, and 62% are current alcohol users.
There was significantly higher alcohol consumption in
the control group than the cancer group (72% vs
47%, p = 0.019). The patients were mostly premeno-
pausal (60%), and 74% were ever-pregnant. The me-
dian live birth count was 2, and 41% patients had a
history of breastfeeding. The mean age at menarche
and mean age at first live birth were not significant
between the two cohorts. Within the cancer cohort,
patients were randomly distributed in terms of the
pathological stage (0–III). Forty-five percent had a
positive family history of breast cancer, and 95% of
patients had ER+/PR+ tumors. Her2neu was positive
in 7.5% of tumor samples, while 15% of patients were
not typed for Her2neu. One patient in the control
group was BRCA-positive, who had undergone a
risk-reduction mastectomy. This patient was excluded
from univariate and multivariate analyses. Further
multivariate logistic regression analysis revealed that
alcohol consumption and post-menopausal status was
significantly different in the two cohorts. The details
of the analysis have been summarized in Table 2.
CpG methylation levels and the “epigenetic clock” analysis
The estimated DNAmAge (derived from the epigen-
etic clock) based on tissue CpG mean methylation
levels highly correlated with the chronological age of
the patients at the time of breast tissue collection (r= 0.712,
p < 0.001, Spearman’s correlation test) (Fig. 1), (Table 3).
This further confirmed the findings we had published
previously that tissue-level methylation can serve as a
predictor for the aging process in an individual [17].
Despite an increasing trend, it can be noted that the tis-
sue epigenetic age varies widely for each individual.
The cancer cohort showed a higher mean of DNAmAge
than the control cohort on univariate analysis (p = 0.021,
Student’s t test) and remained statistically significant even
after matching for age and smoking status (p = 0.009).
(Table 3) To eliminate the effect of age, we regressed the
DNAmAge values over the age variable to calculate the
age acceleration residuals. The cancer cohort exhibited a
significant positive age acceleration (positive residual
coefficient) correlation compared to the control samples
(p < 0.001, Student’s t test) (Fig. 2d). All samples but one
in the cancer cohort were ER+ and/or PR+ (luminal sub-
type). The single basal subtype did not show a positive age
acceleration; however, no conclusion could be drawn from
a single value. Three patients from the luminal subtypes
were Her2+. Though these three patients had a positive
age acceleration with respect to the controls, it was not
significantly different from the Her2-negative cancer co-
hort (RR − 0.001, SE − 0.006, p = 0.237).
Predictors of DNAmAge and age acceleration
residuals—univariate and multivariate analyses and
inverse probability weighted regression adjustment
(IPWRA) analysis
A univariate analysis revealed that age (p < 0.001), breast
cancer status (p = 0.021), smoking (pack years) (p = 0.013),
more than one live birth (p < 0.01), and post-menopausal
status (p < 0.001) were significantly associated with
DNAmAge. However, on the multivariate analysis only
age (p < 0.001), breast cancer status (p = 0.009), and smok-
ing pack years (p = 0.022) remained significant. Since
DNAmAge has a very strong correlation with age of the
individual (r = 0.713), it can be hypothesized that the effect
of breast cancer status or any other covariate will be di-
minished. To adjust for this, we calculated an
age-adjusted measure of DNAmAge as age acceleration
residual, which is independent of the age of the patient
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(vide supra). This can be seen in Fig. 2 where age acceler-
ation residual (p < 0.001) (Fig. 2d) has a stronger correl-
ation than DNAmAge (p = 0.007). A multivariate analysis
on age acceleration residuals revealed that only breast
cancer status (p = 0.009) and smoking pack years (p =
0.022) were significant predictors of this epigenetic vari-
able (Table 3). Further, breast cancer status is a much
stronger predictor (coefficient = 4.489) of increased age ac-
celeration residual than the smoking pack years (coeffi-
cient = 0.178) (Table 2).
In a secondary analysis, we examined the correl-
ation of smoking pack years with the DNAmAge of
the sampled breast tissue. Age acceleration residual
was correlated with tobacco variables (r = 0.21, p =
0.047 for total years of smoking, r = 0.26, p = 0.014
cigarettes per day, and r = 0.26, p = 0.015 smoking
pack years) in the complete cohort. Similar trends
were also noted in the control group (Fig. 3a–f ).
Though a positive correlation was also noted in the
cancer group, it did not reach statistical significance
(Fig. 3g–i). These results need to be interpreted with
caution as the study was not designed initially to
identify smoking as a potential driver of tissue-level
epigenetic changes.
Our study population had a selection bias in the
age of presentation of the cancer and control popula-
tion. This can be identified in Fig. 1, where most of
the patients in the cancer cohort were in the age
group 45 to 65 years whereas the control group were
either below or above this age group. To adjust for
Table 1 Demographic variables of the cancer and control arms
Variables Breast cancer
N (%)/mean
(95% CI)
Controls
N (%)/mean
(95% CI)
p value
Total cohort
samples
40 53
Age (years) 49.7 (46.32–53.02) 45.9 (40.29–51.55) 0.126
Age category 0.742
< 50 years 24 (60%) 30 (57%)
≥ 50 years 16 (40%) 23 (43%)
Ethnicity 0.076
White 31(78%) 49 (92%)
African
Americans
4 (10%) 3 (6%)
Others 5 (13%) 1 (2%)
Ashkenazi
Jew
6 (15%) 3 (6%) 0.162
Height (in.) 64.02 (63.10–64.94) 63.96 (63.19–64.73) 0.45
Weight (lbs) 157.22 (146.54–167.90) 157.50 (148.59–166.41) 0.483
BMI (kg/m2) 0.446
< 18.5 0 (0%) 1 (2%)
18.5–24.9 21 (53%) 22 (42%)
25.0–29.9 8 (20%) 17 (32%)
> 30 11 (28%) 13 (25%)
Tobacco use 0.696
No 25 (63%) 31 (58%)
Yes 15 (38%) 22 (42%)
Smoking
(pack years)
3.73 (1.06–6.41) 3.86 (1.06–6.59) 0.475
Current
alcohol use
0.019
No 20 (52%) 15 (28%)
Yes 18 (47%) 38 (72%)
Positive family
history of
breast cancer
18 (45%) 11 (21%) 0.012
Age at
menarche
(years)
12.37 (11.72–13.03) 12.54 (12.20–12.87) 0.671
Menopausal
status
0.212
Pre-
menopausal
27 (68%) 29 (55%)
Post-
menopausal
13 (33%) 24 (45%)
Ever pregnant 0.266
No 8 (20%) 16 (30%)
Yes 32 (80%) 37 (70%)
No. of times
pregnant
2.6 (1.94–3.25) 1.94 (1.48–2.39) 0.049
Age at first
childbirth
25.73 (23.24–28.99) 25.61 (24.21–27.01) 0.465
Table 1 Demographic variables of the cancer and control arms
(Continued)
Variables Breast cancer
N (%)/mean
(95% CI)
Controls
N (%)/mean
(95% CI)
p value
(years)
Number of live
births
1.97 (1.54–2.40) 1.57 (1.23–1.92) 0.073
Breastfeeding 0.567
No 25 (63%) 30 (57%)
Yes 15 (38%) 23 (43%)
ER/PR status NA
ER+/PR+ 38 (95%) –
ER+/PR- 1 (2.5%) –
ER−/PR+ 0(0)
ER−/PR− 1(2.5%) –
Her2 status NA
Not typed 6 (15%) –
Her− 31 (78%) –
Her+ 3 (7.5%) –
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this, we created an IPWRA model based on predic-
tors of DNAmAge (linear-dependent outcome vari-
able) and breast cancer status (logistic-dependent
treatment variable), accounting for age and smoking
as independent outcome variables and current alcohol
use and menstrual status as independent treatment
variables, to identify the average treatment effect. The
iterations were further bootstrapped to 500 reps to
calculate the 95% CI. The analysis revealed that breast
cancer status was significantly associated with a
higher DNAmAge score with an average treatment
effect of 3.98 years (p = 0.003) (Table 4).
Predictive function of the epigenetic variables
The receiver operating characteristic (ROC) were
plotted to identify the accuracy of the epigenetic var-
iables in predicting breast cancer (Fig. 4). Age is
considered a strong risk factor for breast cancer;
thus, its ROC curve was considered as the baseline
for comparison (AUC = 0.527). Like age, DNAmAge
(AUC = 0.578) was not a good predictor for breast
cancer status, and the curve closely resembled the
age binomial fit model. This can be attributed to age
being a stronger predictor for DNAmAge than breast
cancer. Age difference calculated as the difference of
the epigenetic age from the chronological age did
not reach desired predictive accuracy as well.
Both mean methylation by sample and age acceler-
ation residuals lead to ROC curves that lie above the
reference line (AUC = 0.687 and AUC = 0.689,
respectively) (Fig. 4). The mean age acceleration for
the control cohort was − 1.67 which corresponded to
a sensitivity of 82.5% and specificity of 49.06% with
a positive likelihood ratio 1.62 and negative likeli-
hood ratio 0.35. The mean age acceleration residual
for cancer cohort was 2.21 which corresponded to a
sensitivity of 47.50% and specificity of 75.47% with a
positive likelihood ratio 1.94 and negative likelihood
ratio 0.69. The tradeoff was achieved at − 0.920 with
80% sensitivity and 57% specificity.
Discussion
To our knowledge, this is the first study that has ana-
lyzed the epigenetic age variables of the adjacent
Table 2 Multivariate logistic regression predicting breast cancer
Logistic regression Number of obs 57
LR chi2(9) 25.9
Prob > χ2 0.0021
Log likelihood − 25.488985 Pseudo R2 0.3369
Breast cancer status Odds ratio Std. err. z p > z [95% conf. Interval]
Age 1.11 0.07 1.79 0.07 0.99 1.25
Age of first live birth 1.04 0.08 0.50 0.62 0.89 1.22
Age of menarche 1.33 0.38 0.99 0.32 0.76 2.34
Current alcohol intake 0.21 0.16 − 2.06 0.04 0.05 0.93
BMI 0.95 0.07 − 0.78 0.44 0.82 1.09
Ever breast fed 0.61 0.50 − 0.60 0.55 0.12 3.06
Family history 2.37 1.91 1.07 0.28 0.49 11.51
Post- vs pre-menopausal 0.01 0.02 − 2.60 0.01 0.00 0.32
Smoking (py) 0.89 0.08 − 1.29 0.20 0.74 1.06
Fig. 1 Tissue epigenetic age versus chronological age. DNA
methylation age estimate based on 353 CpGs (y-axis) versus
chronological age. All samples are normal breast tissue samples;
normal tissue samples from cancer patients were obtained from
mastectomy specimens > 3 cm from tumor margin. Samples
(points) are colored by disease status of the donor: red = breast
cancer and green = control. A linear regression line has been
added. Age acceleration is defined as raw residual resulting from
the regression model, i.e., the (signed) vertical distance to the
line. Points above and below the line exhibit positive and
negative epigenetic age acceleration, respectively. The high
Pearson correlation coefficient r = 0.712, (p < 0.001) reflects the
strong linear relationship between DNAmAge and chronological
age at the time of breast sample collection
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“normal” breast tissue in patients with breast cancer.
Our cross-sectional analysis suggests that both
epigenetic age acceleration and mean methylation in
adjacent breast tissue are predictive of breast cancer
status, but these findings require validation in
prospective cohort studies. Age, along with breast
cancer status and smoking, are independent predic-
tors of epigenetic age of breast tissue.
It is unknown what age-related genetic changes
come in effect to increase the incidence of breast
cancer in the age group 45–65 years and whether
the changes are limited to the site of tumor origin
or are present in the entire breast tissue. The
concept of field cancerization is well-known in other
regions of the body where it has been attributed to
exposure to exogenous factors; however, the role of
endogenous factors like chronic cell cycling or
age-related epigenetic silencing of various genetic
pathways in making a tissue more vulnerable to
oncogenic transformation is not fully identified.
Certain aging processes can accelerate or hinder
tumorigenesis in a tissue-specific manner which has
been discussed elsewhere [18]. Its specific role in the
breast cancer is yet to be elucidated.
Our study highlights the treatment effects analysis
which suggests that the normal tissue in the breast
cancer patients was at least half a decade older in
terms of cumulative epigenetic damage in an
age-matched comparison. While this finding may
initially seem to have little clinical significance, it is
interesting to note that the age acceleration residuals
were in complete contrast within the two cohorts.
Unaffected individuals had a negative mean age
acceleration residual, suggesting that the rate of
increase of breast tissue age was slowing down in
terms of chronological age, compared to the patients
with breast cancer who had positive age acceleration
residual, suggesting that the breast tissue was aging at
a faster rate than the individual herself. The ROC
curves further suggest that higher age acceleration in
the breast cancer cohort was specific for breast cancer
occurrence. Although our cross-sectional model does
not lend itself for dissecting cause and effect relation-
ships, the significant age acceleration observed in
patients with luminal breast cancers supports the
hypothesis that DNAmAge of normal breast tissue in
women with breast cancer increases at a higher rate
than in an unaffected individual. As such, our findings
suggest that a breast tissue biomarker of accelerated
aging may exist that could potentially be associated
with the future development of breast cancer.
Future studies will need to test the hypothesis that
breast tissue is more predictive of incident breast
cancer than blood tissue, which has previously been
Table 3 Univariate and multivariate analyses of factors affecting
DNAmAge and age acceleration residuals
Univariate analysis Multivariate analysis
Coef. Std. err. p > t Coef. Std. err. p > t
DNAmAge
Age 0.712 0.039 < 0.001 0.807 0.095 < 0.001
Breast cancer
vs controls
6.551 2.78 0.021 4.489 1.663 0.009
BMI 0.148 0.238 0.534 0.164 0.143 0.256
Current alcohol
use
− 2.833 2.904 0.332 – – –
Smoking (py) 0.407 0.16 0.013 0.177 0.075 0.022
Age at
menarche
0.322 0.959 0.738 0.948 0.49 0.057
Age at first live
birth
0.03 0.251 0.905 – – –
Count of live births
1 2.292 5.494 0.678 − 4.92 3.268 0.137
1+ 14.395 2.887 < 0.001 − 1.536 2.138 0.475
Breast fed 5.286 2.83 0.065 – – –
Post- vs pre-
menopausal
18.645 2.138 < 0.001 − 3.982 3.006 0.19
Hispanic − 5.924 5.018 0.241 − 3.921 3.223 0.228
Race
White − 0.059 5.815 0.992 0.709 3.088 0.819
African
Americans
− 2.142 7.643 0.78 0.196 4.219 0.963
Age Acc. Residuals
Age 0.000 0.039 1 0.095 0.095 0.324
Breast cancer
vs controls
3.878 1.264 0.003 4.489 1.664 0.009
BMI 0.117 0.11 0.288 0.164 0.143 0.256
Current alcohol
use
− 2.484 1.349 0.068 – – –
Smoking (py) 0.174 0.074 0.022 0.178 0.076 0.022
Age at
menarche
0.358 0.454 0.433 0.949 0.491 0.057
Age at first
live birth
− 0.169 0.153 0.274 – – –
Count of live births
1 − 1.598 2.9 0.583 − 4.92 3.268 0.137
1+ 0.041 1.52 0.979 − 1.536 2.138 0.475
Breast fed − 2.28 1.315 0.086 – – –
Post vs
pre-menopausal
− 1.351 1.335 0.314 − 3.982 3.006 0.19
Hispanic 0.636 2.342 0.786 − 3.921 3.223 0.228
Race
White − 1.063 2.685 0.693 0.709 3.088 0.819
African
Americans
1.082 3.529 0.76 0.196 4.219 0.963
Variables in italics are those which reached statistical significance
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shown to have a positive, but relatively weak, pre-
dictive association [14]. This hypothesis is indirectly
supported by the finding that DNA methylation
levels in breast tissue are more predictive of the en-
dogenous hormonal milieu in unaffected women
compared to blood [19]. Thus, it will be interesting
to study whether DNA methylation changes precede
actual occurrence of the breast cancer in patients
with hormone-responsive breast cancers.
The positive association of smoking with the DNA-
mAge as well as age acceleration residual is an inter-
esting and unexpected finding in our study. Previous
studies failed to detect such an effect in blood [20],
liver, or adipose tissue [10]. Taken together, these
findings corroborate the hypothesis that many stress
factors affect epigenetic age acceleration in a
tissue-specific manner. Ever-smokers have been
found to have a modest increase in the incidence of
breast cancer, particularly in females who started
smoking in their adolescence. Although our study
does not include data on the exact time interval
since smoking initiation and/or smoking cessation
and acquisition of data, the association of an overall
impact of smoking on DNA methylation is intriguing
and merits further study.
We recently published our findings that breast
tissue ages faster than blood in unaffected women, as
measured by DNA methylation [17]. From the
current study, we further extend our understanding
of the normal breast tissue, where we identify that
patients with hormone-responsive breast cancer have
higher epigenetic age acceleration compared to
age-matched controls. Given that breast tissue age
could be considered a function of multiple variables
orchestrating in sync in response to endogenous and
exogenous factors during an individual’s lifetime
(such as age of menarche, use of hormone replace-
ment therapy, alcohol use, and others), epigenetic
Fig. 2 Comparison of epigenetic variables between cases and controls. Bar plots depict mean epigenetic age and age acceleration (y-axis)
versus disease status. a Mean methylation levels of each cohort. b DNAmAge of each cohort. c Age acceleration differences. d Age
acceleration residuals. The cancer cohort exhibits a significant positive age acceleration (positive residual coefficient) correlation compared
to controls
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aging may serve as a useful surrogate marker of this
changing internal milieu, and offer insight into future
breast cancer risk.
We acknowledge the limitations of our study,
including the aforementioned small sample size and in-
ability to extrapolate findings to all breast cancer sub-
types. Our study involved mainly luminal breast cancer
samples. We had one ER-negative/PR-negative sample
(which exhibited negative age acceleration) and one ER
+/PR-negative sample, and thus, no definite conclusions
could be drawn from them. We were also not able to
evaluate the effect of BRCA mutations on epigenetic age
acceleration since our study involved only a single BRCA
mutation carrier who had not (yet) developed breast
cancer at the time of sample collection. Further, no sig-
nificant correlation could be drawn based on the
Fig. 3 Correlation of tobacco use variables between cases and controls. DNA methylation age acceleration estimates (y-axis) are depicted for
specific tobacco use variables, including total pack years, total number of years smoking, and cigarettes per day. a–c Analyses for these variables
using the combination of both study cohorts. d–f The same specific variable analyses for the control cohort. g–i Analyses for the cancer cohort.
There is a statistically significant positive correlation between the tobacco variables and the complete cohort, and in the control cases. Though a
positive correlation is noted in breast cancer cases as well, it did not reach a statistical significance
Table 4 Regression adjustment model with inverse showing average treatment effects (ATE) and potential-outcome mean (POmean)
DNAmAge Groups Coef. Bootstrap z p > z [95% conf. interval]
Std. err.
ATE Cancer vs control group 3.98337 1.333459 2.99 0.003 1.369837 6.596902
POmean Control 55.60416 1.642661 33.85 0 52.38461 58.82372
Treatment-effects estimation: Number of obs = 85; Estimator: IPW regression adjustment; Outcome model: linear; Treatment model: logit; Bootstrap Iterations: 500
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pathologic stage of the tumor as the sample size was not
powered for such an analysis. An additional limitation of
our study was the difference in age distribution of the
cancer cohort as compared to the unaffected cohort,
though statistical measures were taken to account for
this difference. Future studies with closely age-matched
cohorts would be helpful to corroborate our findings. Fi-
nally, and of note, we did not isolate any specific cell
type within the whole breast sample for the epigenetic
age analysis. Thus, we cannot account for the specific
cell type, if any, that is primarily responsible for the
DNAmAge acceleration in the normal breast. Future
studies should be considered to determine the epigenetic
ages of individual cell types, as compared to whole tissue
epigenetic age analysis.
Conclusions
In summary, our study demonstrates that epigenetic
age acceleration of the “normal” breast tissue in
patients with luminal breast cancer was significantly
higher than that of unaffected women. We also
observed that the difference was maintained when ad-
justed for potential clinical confounders. Further lar-
ger prospective studies will be required to identify the
temporal trend of the observed epigenetic aging and
its possible use as a predictive biomarker.
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